
The recently published Q1 financial statement from the Danish medtech company Coloplast is pretty much as could be expected, according to analyst Michael Friis Jørgensen from Alm. Brand Markets.
“There are no real surprises anywhere. Turnover is as expected, and Coloplast hangs on to the strong margins, as they have done for some time now. But it was completely as expected. So it is a bit of a non-event,” he tells Medwatch, adding:
Allerede abonnent? Log ind.
Læs hele artiklen
Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app